Business Context and Reporting Period
Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company focused on developing curative therapies for heart disease. This Form 10-Q covers the quarterly period ended June 30, 2026. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of July 30, 2026, there were 224,230,012 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $1.1 million | $1.3 million |
| Net Loss | $(43.4) million | $(62.7) million |
| Net Loss Per Share (Basic & Diluted) | $(0.20) | $(0.29) |
| Operating Expenses | $45.2 million | $65.5 million |
| Cash and Cash Equivalents (as of June 30, 2026) | $78.1 million | |
| Accumulated Deficit (as of June 30, 2026) | $(667.7) million | |
| Net Cash Used in Operating Activities (6 months) | $(22.8) million |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $1.1 million in collaboration revenue for the quarter (and $1.3 million for the six months) stemming from a new agreement with Alnylam Pharmaceuticals entered in March 2026. There was no revenue in the comparable prior-year periods.
- Impairment Loss: A significant non-cash impairment loss of $21.8 million was recorded in Q2 2026 related to the early termination of the lease for the Genetic Medicine Manufacturing Center (GMMC) in Union City. This resulted in the write-down of leasehold improvements and manufacturing equipment.
- Lease Termination: A net loss of $1.4 million was recognized due to the GMMC lease termination, including the forfeiture of a $1.8 million security deposit and a $0.3 million termination fee.
- Operating Expenses: Total operating expenses increased by 88% for the quarter and 27% for the six months compared to the prior year, primarily driven by the impairment and lease termination charges. Excluding these unusual items, core R&D and G&A expenses decreased due to workforce reductions implemented in March 2025.
- Warrant Expirations: Series B Warrants to purchase 27.3 million shares expired on June 30, 2026, while 6.95 million shares were issued upon the exercise of remaining Series B Warrants during the quarter.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash of $78.1 million is sufficient to fund operations for at least the next twelve months. However, the company expects to continue incurring significant losses and will require substantial additional capital to complete development and commercialization.
- Clinical Progress:
- TN-201 (HCM): Interim data from the MyPEAK-1 trial showed improvements in hypertrophy and symptom burden. The company plans to present one-year Cohort 2 and two-year Cohort 1 data in Q4 2026.
- TN-401 (ARVC): Interim data from the RIDGE-1 trial demonstrated dramatic reductions in arrhythmia burden. Interim Cohort 2 results are expected in Q4 2026.
- TN-301 (HFpEF/DMD): Preclinical data supports advancement toward clinical trials. The company plans to initiate a proof-of-activity Phase 2 trial in the second half of 2027.
- Manufacturing Strategy: Following the closure of the GMMC facility, the company plans to transfer its AAV manufacturing process to a contract development manufacturing organization (CDMO).
- Key Risks:
- Nasdaq Listing: The company received notice of non-compliance with the $1.00 minimum bid price requirement in January 2026. It transferred to the Nasdaq Capital Market in July 2026 to gain additional time to regain compliance. Failure to do so could result in delisting.
- Capital Needs: Inability to raise additional capital on acceptable terms could force the company to delay or terminate development programs.
- Regulatory Uncertainty: Risks associated with the FDA review process, including potential clinical holds (a hold was placed and lifted on MyPEAK-1 in late 2025) and the evolving regulatory landscape for gene therapies.
Investor Verification Checklist
- Verify the timeline and terms for regaining compliance with Nasdaq listing requirements to avoid delisting.
- Confirm the status of the transition from internal manufacturing (GMMC) to a CDMO and any associated regulatory filings.
- Monitor the upcoming Q4 2026 data readouts for TN-201 and TN-401, which are critical for pivotal trial planning.
- Assess the company's cash burn rate relative to the $78.1 million cash balance to determine the urgency of future financing.
- Review the details of the Alnylam collaboration agreement to understand the revenue recognition schedule and potential milestone payments.